Akynzeo (Netupitant and Palonosetron) and Sutent
Determining the interaction of Akynzeo (Netupitant and Palonosetron) and Sutent and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using SUNItinib together with palonosetron can increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment with these medications, whether together or alone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Sunitinib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In an open, positive control trial of 24 patients aged 20 to 87 years with advanced malignancies, the maximum QTcF (Fridericia's correction) mean change from baseline was 9.6 msec at plasma concentrations seen with normal recommended doses of sunitinib and 15.4 msec at plasma concentrations approximately twice those seen with recommended doses, compared to 5.6 msec for the positive control of moxifloxacin 400 mg. Elsewhere, increases in the QTc interval to over 500 msec occurred in 0.5% and changes from baseline in excess of 60 msec occurred in 1.1% of 450 solid tumors patients; both of these parameters are recognized as potentially significant changes. Torsade de pointes arrhythmia has been observed in less than 0.1% of sunitinib-exposed patients. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).
MANAGEMENT: Caution is recommended if sunitinib is used in combination with other drugs that can prolong the QT interval. Periodic monitoring with on-treatment electrocardiograms and serum electrolytes (magnesium, potassium) should be considered. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: netupitant / palonosetron
Brand name: Akynzeo
Synonyms: Akynzeo
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Akynzeo (Netupitant and Palonosetron)-Suvorexant
- Akynzeo (Netupitant and Palonosetron)-Swabflush flush
- Akynzeo (Netupitant and Palonosetron)-SwabFlush Saline Flush
- Akynzeo (Netupitant and Palonosetron)-Sweet vernal/orchard/perennial rye/timothy/kentucky blue grass mixed pollen allergen extract Sublingual
- Akynzeo (Netupitant and Palonosetron)-Swiss Kriss
- Akynzeo (Netupitant and Palonosetron)-Sx1 Medicated Post-Operative System
- Sutent-Akynzeo for injection
- Sutent-Akynzeo Intravenous
- Sutent-Ala Hist IR
- Sutent-Ala Hist PE
- Sutent-Ala Quin Cream
- Sutent-Ala Scalp